UnitedHealth Group has posted a first-quarter 2022 adjusted EPS of $5.49, exceeding expectations by 1.7%, with revenues of $80.1 billion surpassing consensus estimates by 1.9%. Analysts highlight that the stock, currently valued at $848.00, remains undervalued and presents an opportunity for investors to accumulate shares, particularly as profits are expected to grow by 50% in the coming years. Despite one cautionary sign, UnitedHealth's low beta indicates stability, and its long-term growth prospects of 14.8% further enhance its attractiveness in a competitive market.
“UnitedHealth Group · has intrinsic value · stock · $848.00”
“UnitedHealth Group · is currently undervalued · stock · true”
“UnitedHealth Group · is expected to grow profits · over the next couple of years · 50%”
“UnitedHealth Group · has a low beta · indicating stability · true”
“UnitedHealth Group · provides a potential opportunity to buy · at low prices · true”
“UnitedHealth Group · will have higher cash flow · in the future · true”
“UNH · is a good time to accumulate · more holdings · true”
“UNH · is not fully reflected · in the current share price · true”
“UnitedHealth Group · has 1 warning sign · to consider · true”
“UnitedHealth · reported first-quarter 2022 adjusted EPS of · $5.49 · which beat the Zacks Consensus Estimate by 1.7%”
“UnitedHealth reported first-quarter 2022 adjusted EPS · of · $5.49”
“UnitedHealth · reported first-quarter 2022 adjusted EPS of · $5.49 · which beat the Zacks Consensus Estimate by 1.7%.”